Skip to main content
Thank you for visiting nature.com. You are using a browser version
with limited support for CSS. To obtain the best experience, we
recommend you use a more up to date browser (or turn off
compatibility mode in Internet Explorer). In the meantime, to
ensure continued support, we are displaying the site without styles
and JavaScript.
Advertisement
[image]
[image]
•  View all journals
•  
Search
•  Log in
•  Content Explore content
•  About the journal
•  Publish with us
•  Subscribe
•  Sign up for alerts
•  RSS feed
1. nature 
2. pediatric research 
3. articles 
4. article
Show authors
•  Article
•  Published: 01 June 2000


Enzyme Replacement Therapy
in a Feline Model of MPS VI:
Modification of Enzyme
Structure and Dose Frequency
•  Sharon Byers1,
•  Allison C Crawley1,
•  Leanne K Brumfield1,
•  Jacqueline D Nuttall1 &
•  …
•  John J Hopwood1 
Pediatric Research volume 47, pages 743–749 (2000)Cite this article
•  1453 Accesses
•  38 Citations
•  Metrics details
Abstract
Enzyme replacement therapy (ERT) in the MPS VI cat is effective at
reducing or eliminating pathology in most connective tissues. One
exception is that cartilage and chondrocytes remained distended
with extensive lysosomal vacuolation after long-term, high-dose
ERT. In this study, we demonstrate that recombinant human N-
acetylgalactosamine-4-sulphatase (4S) is taken up by chondrocytes
via a mannose-6-phosphate-dependent mechanism and is effective
at removing MPS storage. In vitro, the penetration of 4S into
articular cartilage is low (partitioning coefficient = 0.06) and i.v.
administered enzyme does not distribute significantly into articular
cartilage in vivo. To alter the tissue distribution of 4S, the enzyme
was coupled to ethylene diamine or poly-L-lysine, increasing its
overall charge and diffusion into cartilage, and the dosing


frequency of unmodified 4S was increased. Modification resulted in
active 4S that maintained its ability to correct MPS storage and
increased the partitioning coefficient of 4S into cartilage by 77%
and 50% for ethylene diamine and poly-L-lysine, respectively.
However, in vivo ERT studies demonstrated that response to therapy
was not significantly improved by either the enzyme modifications
or change to the dosing regimen, when compared with ERT with
unmodified enzyme. Distribution experiments indicated the
majority of enzyme is taken up by the liver irrespective of
modification. To optimize therapy and improve the amount of
enzyme reaching cartilage and other tissues demonstrating poor
uptake, it may be necessary to bypass the liver or prolong plasma
half-life so that proportionately more enzyme is delivered to other
tissues.
Similar content being viewed by others
[image]
Quantitative ultrasound classification of healthy and
chemically degraded ex-vivo cartilage
Article Open access 01 July 2025
[image]
A novel prostaglandin E receptor 4 (EP4) small
molecule antagonist induces articular cartilage
regeneration
Article Open access 08 March 2022
[image]
In vivo potency assay for the screening of bioactive
molecules on cartilage formation
Article 31 March 2022


Log in or create a free account to read this
content
Gain free access to this article, as well as selected content from this
journal and more on nature.com
 Access through your institution
or
 Sign in or create an account 
[image] Continue with Google 
[image] Continue with ORCiD 
Abbreviations
MPS:
mucopolysaccharidoses
MPS VI:
mucopolysaccharidosis type VI
4S:
N-acetylgalactosamine-4-sulphatase
ED:
ethylene diamine
PL:
poly-L-lysine
4SED:


4S coupled to ethylene diamine
4SPL:
4S coupled to poly-L-lysine
ERT:
enzyme replacement therapy
M-6-P:
mannose-6-phosphate
BBB:
blood-brain barrier
EDC:
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
NHS:
N-hydroxysulfosuccinimide
References
1. Hopwood JJ 1991 Lysosomal function and disease. Todays
Life Sci 34: 24–33
Google Scholar 
2. Neufeld EF, Muenzer J 1995 The mucopolysaccharidoses. In:
Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The Metabolic
and Molecular Basis of Inherited Disease. McGraw-Hill, New
York, pp 2465–2494
Google Scholar 
3. Byers S, Rozaklis T, Brumfield LK, Ranieri E, Hopwood JJ


1998 Glycosaminoglycan accumulation and excretion in the
mucopolysaccharidoses: characterization and basis of a
diagnostic test for MPS. Mol Genet Metab 65: 282–290
Article  CAS  PubMed  Google Scholar 
4. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM,
Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff
CE, Grewal RP, Yu KT 1991 Replacement therapy for
inherited enzyme deficiency: macrophage-targeted
glucocerebrosidase for Gaucher's disease. N Engl J Med 324:
1464–1470
Article  CAS  PubMed  Google Scholar 
5. Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff
R, Hatem C, Kurtzberg J, Markert ML, Kobayashi RH,
Kobayashi AL, Abuchowski A 1987 Treatment of adenosine
deaminase deficiency with polyethylene glycol-modified
adenosine deaminase. N Engl J Med 316: 589–596
Article  CAS  PubMed  Google Scholar 
6. Levy Y, Hershfield MS, Fernandez-Mejia C, Polmar SH,
Scudiery D, Berger M, Sorenson RU 1988 Adenosine
deaminase deficiency with late onset of recurrent infections:
response to treatment with polyethylene glycol-modified
adenosine deaminase. J Pediatr 113: 312–317
Article  CAS  PubMed  Google Scholar 
7. Gibson GJ, Saccone GTP, Brooks DA, Clements PR, Hopwood
JJ 1987 Human N-acetylgalactosamine-4-sulphate sulphatase:
purification, monoclonal antibody production and native and
subunit Mr values. Biochem J 248: 755–764
Article  CAS  PubMed  PubMed Central  Google Scholar 
8. Freeman C, Hopwood JJ 1989 Sanfilippo D syndrome:
estimation of N-acetylglucosamine-6-sulphatase activity with
a radiolabelled monosulfated disaccharide substrate. Anal
Biochem 176: 244–248


Article  CAS  PubMed  Google Scholar 
9. Freeman C, Hopwood JJ 1992 Human α-L-iduronidase:
catalytic properties and an integrated role in the lysosomal
degradation of heparan sulphate. Biochem J 282: 899–908
Article  CAS  PubMed  PubMed Central  Google Scholar 
10. Bielicki J, Freeman C, Clements PR, Hopwood JJ 1990
Human liver iduronate-2-sulphatase: purification,
characterization and catalytic properties. Biochem J 271: 75–
86
Article  CAS  PubMed  PubMed Central  Google Scholar 
11. Bielicki J, Hopwood JJ 1991 Human liver N-
acetylgalactosamine-6-sulphatase: purification,
characterization and catalytic properties. Biochem J 279: 515–
520
Article  CAS  PubMed  PubMed Central  Google Scholar 
12. Mahuran D, Clements P, Hopwood JJ 1983 A rapid four
column purification of 2-deoxy-D-glucoside-2-sulphamate
sulphohydrolase from human liver. Biochim Biophys Acta 757:
359–365
Article  CAS  PubMed  Google Scholar 
13. Weber B, Blanch L, Clements PR, Scott HS, Hopwood JJ 1996
Cloning and expression of the gene involved in Sanfilippo B
syndrome (mucopolysaccharidosis type IIIB). Hum Mol Genet
5: 771–777
Article  CAS  PubMed  Google Scholar 
14. Sasaki T, Sukegawa K, Masue M, Fukuda S, Tomatsu S, Orii T
1991 Purification and partial characterization of α-N-
acetylglucosaminidase from human liver. J Biochem 110:
842–846
Article  CAS  PubMed  Google Scholar 


15. Meikle PJ, Whittle AM, Hopwood JJ 1995 Human acetyl-
coenzyme A: α-glucosaminide N-acetyltransferase. Biochem J
308: 327–333
Article  CAS  PubMed  PubMed Central  Google Scholar 
16. Norden AGW, Tennant LL, O'Brien JS 1974 GM1 ganglioside
β-galactosidase A: Purification and studies of the enzyme
from human liver. J Biol Chem 249: 7969–7976
CAS  PubMed  Google Scholar 
17. Musa BU, Doe RP, Seal US 1965 Purification and properties of
human liver β-glucuronidase. J Biol Chem 240: 2811–2816
CAS  PubMed  Google Scholar 
18. Wilson PJ, Morris CP, Anson DS, Occhiodoro T, Bielicki J,
Clements PR, Hopwood JJ 1990 Hunter syndrome: isolation
of an iduronate-2-sulphatase cDNA clone and analysis of
patient DNA. Proc Natl Acad Sci USA 87: 8531–8535
Article  CAS  PubMed  PubMed Central  Google Scholar 
19. Scott HS, Anson DS, Orsborn AM, Nelson PV, Clements PR,
Morris CP, Hopwood JJ 1991 Human α-: -iduronidase: cDNA
isolation, expression and alternatively spliced transcripts. Proc
Natl Acad Sci USA 88: 9695–9699
Article  CAS  PubMed  PubMed Central  Google Scholar 
20. Schuchman EH, Jackson CE, Desnick RJ 1990 Human
arylsulfatase B: MOPAC cloning, nucleotide sequence of a
full-length cDNA and regions of aminoacid identity with
arylsulfatases A and C. Genomics 6: 149–158
Article  CAS  PubMed  Google Scholar 
21. Peters C, Schmidt B, Rommerskirch W, Rupp K, Zuhlsdorf M,
Vingron M, Meyer HE, Pohlmann R, von Figura K 1990
Phylogenetic conservation of arylsulfatases: cDNA cloning
and expression of human arylsulfatase B. J Biol Chem 265:


3374–3381
CAS  PubMed  Google Scholar 
22. Scott HS, Blanch L, Guo X-H, Freeman C, Orsborn A, Baker E,
Sutherland GR, Morris CP, Hopwood JJ 1995 Cloning of the
sulphamidase gene and identification of mutations in
Sanfilippo A syndrome. Nat Genet 11: 465–467
Article  CAS  PubMed  Google Scholar 
23. Robertson DA, Freeman C, Morris CP, Hopwood JJ 1992 A
cDNA clone for human glucosamine-6-sulphatase reveals
differences between arylsulphatases and non-arylsulphatases.
Biochem J 288: 539–544
Article  CAS  PubMed  PubMed Central  Google Scholar 
24. Tomatsu S, Fukuda S, Masue M, Sukegawa K, Fukao T,
Yamagishi A, Hori T, Iwata H, Ogawa T, Nakashima Y, Hanyu
Y, Hashimoto T, Titani K, Oyama R, Suzuki M, Yagi K,
Hayashi Y, Orii T 1991 Morquio disease: isolation,
characterization and expression of full length cDNA for
human N-acetylgalactosamine-6-sulphate sulphatase. Biochem
Biophys Res Commun 181: 677–683
Article  CAS  PubMed  Google Scholar 
25. Oshima A, Kyle JW, Miller RD, Hoffman JW, Powell PP,
Grubb JH, Sly WS, Tropak M, Guise KS, Gravel RA 1987
Cloning, sequencing and expression of cDNA for human β-
glucuronidase. Proc Natl Acad Sci USA 84: 685–689
Article  CAS  PubMed  PubMed Central  Google Scholar 
26. Oshima A, Tsuji A, Nagao Y, Sakuraba H, Suzuki Y 1988
Cloning, sequencing and expression of cDNA for human β-
galactosidase. Biochem Biophys Res Commun 157: 238–244
Article  CAS  PubMed  Google Scholar 
27. Anson DS, Taylor JA, Bielicki J, Harper GS, Peters C, Gibson


GJ, Hopwood JJ 1992 Correction of human
mucopolysaccharidosis type-VI fibroblasts with recombinant
N-acetylgalactosamine-4-sulphatase. Biochem J 284: 789–794
Article  CAS  PubMed  PubMed Central  Google Scholar 
28. Bielicki J, Hopwood JJ, Wilson PJ, Anson DS 1993
Recombinant human iduronate-2-sulphatase: correction of
mucopolysaccharidosis-type II fibroblasts and
characterization of the purified enzyme. Biochem J 289: 241–
246
Article  CAS  PubMed  PubMed Central  Google Scholar 
29. Kakkis ED, Matynia A, Jonas AJ, Neufeld EF 1994
Overexpression of the human lysosomal enzyme α-L-
iduronidase in chinese hamster ovary cells. Protein Expr Purif
5: 225–232
Article  CAS  PubMed  Google Scholar 
30. Unger EG, Durrant J, Anson DS, Hopwood JJ 1994
Recombinant α-L-iduronidase: characterization of the purified
enzyme and correction of mucopolysaccharidosis type I
fibroblasts. Biochem J 303: 43–49
Article  Google Scholar 
31. Bielicki J, Hopwood JJ, Melville EL, Anson DS 1998
Recombinant human sulphamidase: expression, amplification,
purification and characterization. Biochem J 329: 145–150
Article  CAS  PubMed  PubMed Central  Google Scholar 
32. Litjens T, Bielicki J, Anson DS, Friderici K, Jones MZ,
Hopwood JJ 1997 Expression, purification and
characterization of recombinant caprine N-
acetylglucosamine-6-sulphatase. Biochem J 327: 89–94
Article  CAS  PubMed  PubMed Central  Google Scholar 
33. Bielicki J, Fuller M, Guo X-H, Morris CP, Hopwood JJ, Anson


DS 1995 Expression, purification and characterization of
recombinant human N-acetylgalactosamine-6-sulphatase.
Biochem J 311: 333–339
Article  CAS  PubMed  PubMed Central  Google Scholar 
34. Gehrmann MC, Opper M, Sedlacek HH, Bosslet K, Czech J
1994 Biochemical properties of recombinant human β-
glucuronidase synthesized in baby hamster kidney cells.
Biochem J 301: 821–828
Article  CAS  PubMed  PubMed Central  Google Scholar 
35. Shull RM, Kakkis ED, McEntee MF, Kania SA, Jonas AJ,
Neufield E 1995 Enzyme replacement therapy in a canine
model of Hurler syndrome. Proc Natl Acad Sci USA 91:
12937–12941
Article  Google Scholar 
36. Sands MS, Vogler C, Kyle JW, Grubb JH, Levy B, Galvin N,
Sly WS, Birkenmeier EH 1994 Enzyme replacement therapy
for murine mucopolysaccharidosis type VII. J Clin Invest 93:
2324–2331
Article  CAS  PubMed  PubMed Central  Google Scholar 
37. Crawley AC, Brooks DA, Muller VJ, Petersen BA, Isaac EL,
Bielicki J, King BM, Boulter CD, Moore AJ, Fazzalari NL,
Anson DS, Byers S, Hopwood JJ 1996 Enzyme replacement
therapy in a feline model of Maroteaux-Lamy syndrome. J
Clin Invest 97: 1864–1873
Article  CAS  PubMed  PubMed Central  Google Scholar 
38. Crawley AC, Niedzielski KH, Isaac EL, Davey RCA, Byers S,
Hopwood JJ 1997 Enzyme replacement therapy from birth in
a feline model of mucopolysaccharidosis type VI. J Clin Invest
99: 651–662
Article  CAS  PubMed  PubMed Central  Google Scholar 


39. Byers S, Nuttall JD, Crawley AC, Hopwood JJ, Smith K,
Fazzalari NL 1997 Effect of enzyme replacement therapy on
bone formation in a feline model of mucopolysaccharidosis
type VI. Bone 21: 425–431
Article  CAS  PubMed  Google Scholar 
40. Hopwood JJ, Muller V, Harrison JR, Carey WF, Elliott H,
Robertson EF, Pollard AC 1982 Enzymatic diagnosis of the
mucopolysaccharidoses: experience of 96 cases diagnosed in a
5-year period. Med J Aust 1: 257–260
Article  CAS  PubMed  Google Scholar 
41. Bradford MM 1976 A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the
principle of protein-dye binding. Anal Biochem 72: 248–254
Article  CAS  PubMed  Google Scholar 
42. Hoare DG, Koshland DE 1967 A method for the quantitative
modification and estimation of carboxylic acid groups in
proteins. J Biol Chem 242: 2447–2453
CAS  PubMed  Google Scholar 
43. Griffen DE, Giffels J 1982 Study of protein characteristics that
influence entry into the cerebrospinal fluid of normal mice
and mice with encephalitis. J Clin Invest 70: 289–295
Article  Google Scholar 
44. Staros JV, Wright RW, Swingle DM 1986 Enhancement by N-
hydroxysulfosuccinimide of water-soluble carbodiimide-
mediated coupling reactions. Anal Biochem 156: 220–222
Article  CAS  PubMed  Google Scholar 
45. Maroudas A 1976 Transport of solutes through cartilage:
permeability to large molecules. J Anat 122: 335–347
CAS  PubMed  PubMed Central  Google Scholar 


46. Kirk RW, Bistner SI 1985 Handbook of Veterinary Procedures
and Emergency Treatment. WB Saunders, Philadelphia, pp
592
47. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H,
Meunier PJ, Ott SM, Recker RR 1987 Bone
histomorphometry: standardization of nomenclature, symbols
and units. J Bone Miner Res 2: 595–610
Article  CAS  PubMed  Google Scholar 
48. Jones MZ, Brumfield LK, King BM, Hopwood JJ, Byers S 1999
Recombinant caprine 3H-[N-acetylglucosamine-6-sulphatase]
and human 3H-[N-acetylgalactosamine-4-sulphatase]: plasma
clearance, tissue distribution and cellular uptake in the rat. J
Mol Neurosci 11: 223–232
Article  Google Scholar 
49. Fillat C, Simonaro CM, Yeyati PL, Abkowitz JL, Haskins ME,
Schuchman EH 1996 Arylsulfatase B activities and
glycosaminoglycan levels in retrovirally transduced
mucopolysaccharidosis type VI cells. J Clin Invest 98: 497–502
Article  CAS  PubMed  PubMed Central  Google Scholar 
50. Dunstone JR 1960 Ion-exchange reactions between cartilage
and various cations. Biochem J 77: 164–170
Article  CAS  PubMed  PubMed Central  Google Scholar 
51. Comper WD, Laurent TC 1978 Physiological function of
connective tissue polysaccharides. Physiol Rev 58: 255–315
Article  CAS  PubMed  Google Scholar 
52. Triguero D, Buciak JD, Yang J, Pardridge WM 1989 Blood-
brain barrier transport of cationized immunoglobulin G:
Enhanced delivery compared to native protein. Proc Natl Acad
Sci USA 86: 4761–4765
Article  CAS  PubMed  PubMed Central  Google Scholar 


53. Pardridge WM, Triguero D, Buciak J, Yang J 1990 Evaluation
of cationized rat albumin as a potential blood-brain barrier
drug transport vector. J Pharmacol Exp Ther 255: 893–899
CAS  PubMed  Google Scholar 
54. Shimon-Hophy M, Wadhwani KC, Chandrasekaran K, Larson
D, Smith QR, Rapoport SI 1991 Regional blood-brain barrier
transport of cationized bovine serum albumin in awake rats.
Am J Physiol 30: R478–R483
Google Scholar 
55. dosSantos WLC, Rahman J, Klein N, Male DK 1995
Distribution and analysis of surface charge on brain
endothelium in vitro and in situ. Acta Neuropathol 90: 305–311
Article  CAS  Google Scholar 
56. Triguero D, Biciak J, Pardridge W 1990 Capillary depletion
method for quantification of blood-brain barrier transport of
circulating peptides and plasma proteins. J Neurochem 54:
1882–1885
Article  CAS  PubMed  Google Scholar 
57. Poduslo JF, Curran GL 1996 Polyamine modification
increases the permeability of proteins at the blood-nerve and
blood-brain barriers. J Neurochem 66: 1599–1609
Article  CAS  PubMed  Google Scholar 
58. Brooks DA, King BM, Crawley AC, Byers S, Hopwood JJ 1997
Enzyme replacement therapy in mucopolysaccharidosis type
VI: evidence for immune responses and altered efficacy of
treatment in animal models. Biochim Biophys Acta 1363: 203–
216
Article  Google Scholar 
59. Kushner I, Somerville JA 1971 Permeability of human
synovial membrane to plasma proteins. Arthritis Rheum 14:


560–570
Article  CAS  PubMed  Google Scholar 
Download references
Author information
Authors and Affiliations
1. Department of Chemical Pathology, Lysosomal Diseases
Research Unit, Women's and Children's Hospital, S.A. 5006,
North Adelaide, Australia
Sharon Byers, Allison C Crawley, Leanne K
Brumfield, Jacqueline D Nuttall & John J Hopwood
Authors
1. Sharon Byers
View author publications
Search author on:PubMed Google Scholar
2. Allison C Crawley
View author publications
Search author on:PubMed Google Scholar
3. Leanne K Brumfield
View author publications
Search author on:PubMed Google Scholar
4. Jacqueline D Nuttall
View author publications
Search author on:PubMed Google Scholar
5. John J Hopwood


View author publications
Search author on:PubMed Google Scholar
Additional information
Supported by the National Health and Medical Research Council of
Australia and CSL Ltd., Commonwealth Serum Laboratories,
Melbourne, VIC, Australia.
Rights and permissions
Reprints and permissions
About this article
Cite this article
Byers, S., Crawley, A., Brumfield, L. et al. Enzyme Replacement
Therapy in a Feline Model of MPS VI: Modification of Enzyme
Structure and Dose Frequency. Pediatr Res 47, 743–749 (2000).
https://doi.org/10.1203/00006450-200006000-00010
Download citation
•  Received: 28 July 1999
•  Accepted: 31 January 2000
•  Issue date: 01 June 2000
•  DOI: https://doi.org/10.1203/00006450-200006000-00010
Share this article
Anyone you share the following link with will be able to read this


content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy shareable link to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative
This article is cited by
•  Early initiation of enzyme replacement therapy
improves metabolic correction in the brain tissue
of aspartylglycosaminuria mice
○  Ulla Dunder
○  Pirjo Valtonen
○  Ilkka Mononen
Journal of Inherited Metabolic Disease (2010)
•  Reversed papilledema in an MPS VI patient with
galsulfase (Naglazyme®) therapy
○  Selim T. Koseoglu
○  Paul Harmatz
○  Helen Nicely
International Ophthalmology (2009)
Advertisement
[image]
Explore content


•  Research articles
•  Reviews & Analysis
•  News & Comment
•  Podcasts
•  Videos
•  Current issue
•  Collections
•  Follow us on Twitter
•  Subscribe
•  Sign up for alerts
•  RSS feed
About the journal
•  Journal Information
•  About the Editors
•  Contact
•  About the Partners
•  For Advertisers
•  Subscribe
•  Announcements
Publish with us
•  For Authors & Referees
•  Language editing services
•  Open access funding
•  Submit manuscript
Search
Search articles by subject, keyword or author


Show results from All journals This journal
Search
Advanced search
Quick links
•  Explore articles by subject
•  Find a job
•  Guide to authors
•  Editorial policies
Pediatric Research (Pediatr Res)
ISSN 1530-0447 (online)
ISSN 0031-3998 (print)
nature.com sitemap
About Nature Portfolio
•  About us
•  Press releases
•  Press office
•  Contact us
Discover content
•  Journals A-Z
•  Articles by subject
•  protocols.io
•  Nature Index
Publishing policies
•  Nature portfolio policies
•  Open access


Author & Researcher services
•  Reprints & permissions
•  Research data
•  Language editing
•  Scientific editing
•  Nature Masterclasses
•  Research Solutions
Libraries & institutions
•  Librarian service & tools
•  Librarian portal
•  Open research
•  Recommend to library
Advertising & partnerships
•  Advertising
•  Partnerships & Services
•  Media kits
•  Branded content
Professional development
•  Nature Awards
•  Nature Careers
•  Nature Conferences
Regional websites
•  Nature Africa
•  Nature China
•  Nature India
•  Nature Japan
•  Nature Middle East
•  Privacy Policy
•  Use of cookies


•  Your privacy choices/Manage cookies
•  Legal notice
•  Accessibility statement
•  Terms & Conditions
•  Your US state privacy rights
[image]
© 2025 Springer Nature Limited


[image]


